Amyloid-beta (A) peptides are considered to be the cause of neuronal and synaptic cell death in Alzheimer's disease (AD) since approximately 100 years. To date, it is assumed that A-peptides arise from the proteolytic cleavage of the amyloid precursor protein (APP). However, within the APP gene, a nested gene called ALZheimer ASsociated (ALZAS) exists, which includes the entire A 42 -sequence and thus may also be the origin of various A-species. Here, we firstly confirmed expression and the postulated amino acid sequence of ALZAS and revealed the binding of selected monoclonal A-antibodies to A-and ALZAS protein. We confirmed the specificity of the anti-ALZAS antibody to ALZAS by protein sequence analysis. This anti-ALZAS antibody detects the same amino acid sequence as the autoantibody found in human blood of AD patients. Since no detailed data are currently available concerning ALZAS expression and the amount, localization and function of ALZAS protein in human cells and tissue, we performed gene (over)expression experiments on transcriptional and translational level. We verified a considerably lower mRNA amount of ALZAS compared to the host gene APP. Nevertheless, ALZAS transcription and translation seems to be heavily regulated in different human tissues and cells. Artificially increased mRNA levels of ALZAS did not led to an enhanced protein amount or considerable increase in cell death. Notably, cell localization of the ALZAS protein showed accordance to endosomes indicating that ALZAS, which contains the whole transmembrane domain of APP, might be a peripheral membrane protein. Since endosome dysfunctions are a characteristic event in early stages of AD and the highest ALZAS-autoantibody levels were already detected in early AD stages, ALZAS might play a crucial role in AD pathology and could possibly be a further diagnostic marker.
Introduction
reveal correlations between ALZAS expression and age, tissue/cell type or disease and (III) investigate the role of ALZAS in human cell metabolism by identification the localization of ALZAS in human cells.
Figure 1. Molecular structure of the human APP gene and the nested gene ALZAS.
The ALZAS gene is located within the human APP gene on chromosome 21. APP isoforms are encoded by up to 18 exons, while all include parts of the ALZAS gene. The coding sequence of ALZAS (red-green) starts in exon 16 of APP (NCBI accession number NG_007376, nucleotide 278195), excludes intron 16 and extends into intron 17 (NG_007376, nucleotide 284137). The derived amino acid sequence of ALZAS contains the whole A 42 -sequence, cutting sites for -, and -secretases and a C-terminal sequence of 12 amino acids (anti-ct12) derived from intron 17 (green; including stop codon) that is recognized by an endogenous autoantibody from AD patients. Postulated cell localization and A-cleavage products of ALZAS are labeled.
Materials and Methods

Human tissue samples
All human tissue samples were from non-AD controls and AD patients differing in age and sex (Table S1 ). The tissue samples were obtained post mortem (post mortem time <24 hrs, kindly provided by Prof. Jellinger, University of Technology, Vienna), postnatal, in the lifetime or from transplant following informed consent of the subjects. All samples were stored at -80°C until required. Working with human tissue samples were in accordance with the Helsinki convention and approved by Ethical Committee of the University of Dresden (EK197092004).
Total RNA isolation
Total RNA was isolated from human tissue using RNeasy Lipid Tissue Mini Kit (Qiagen) or PAXgene Blood RNA Kit (PreAnalytix). Total RNA from human neuroblastoma SH-SY5Y cells was isolated with RNeasy Mini Kit (Qiagen) in accordance with the manufacturer's instructions.
Details regarding RNA integrity are provided in the Supplementary section "RNA analysis".
Protein extraction
Human tissue (Total protein isolation)
Proteins from human tissue (Table S1 ) were extracted using a tissue grind and protein lysis buffer comprised of PBS, 0.5% v/v Triton X-100 (both Thermo Fisher Scientific), 0.2% v/v SDS (Carl Roth) and protease inhibitors (Sigma-Aldrich or Roche). The tissue lysate was sonicated for 5 min and afterwards incubated for 5 min at 99°C. The tissue lysate was centrifuged for 5 min at 4°C and 20,000 g. The supernatant was collected and stored at ≤-20°C until required.
Fractionated protein isolation (Membrane protein protocol)
The tissue sample of a non-demented patient (Cortex, sample 118; Table S1 ) was homogenized in 300 µl protein lysis buffer and centrifuged for 5 min at 4°C and 900 g. Supernatant (s1, watersoluble and membrane proteins) was collected and again centrifuged for 30 min at 4°C and 230,000 g. The supernatant (s2, water-soluble proteins) was separated and the pellet (membrane proteins) was resuspended in 200 µl protein lysis buffer. All samples were stored at ≤-20°C until usage.
Adherent cells
To isolate proteins from adherent human neuroblastoma cells SH-SY5Y, the medium was removed and the cells washed with PBS. To lyse the cells, protein lysis buffer was added. A modified protocol was applied where secreted protein, protein being part of death (detached) cells and protein in attached cells (cell extract) required separation. For that, the medium was centrifuged for 5 min at 14,000 g and the supernatant (secreted proteins) and the death cells were separated. The death cells were resuspended in protein lysis buffer. All lysates were stored at ≤-20°C.
Gene expression (mRNA) analysis using RT-qPCR
1-step qPCR was performed with Brilliant II SYBR Green QRT-PCR Master Mix Kit (Agilent Technologies) according to manufacturer's instructions. For 2-step qPCR, total RNA was first reverse transcribed with QuantiTect Reverse Transcription Kit (Qiagen) to generate cDNA and afterwards amplified using QuantiTect SYBR Green PCR Kit (Qiagen) following the manufacturer's instructions. All qPCRs were performed in a Mx3000P cycler (Agilent Technologies). Cycling conditions for 1-step RT-qPCR: 25 min 50°C / 15s 95°C / 45 cycles of 15s 94°C, 20s 57°C, 30s 72°C (modified cycling conditions comprised an additional temperature plateau for 15s at 77°C) / 1 cycle of 1 min 95°C, 30s 55°C, 30s 95°C. Cycling conditions for 2-step RT-qPCR: 15 min 95°C / 40-45 cycles of 15s 94°C, 30s 57°C, 30s 72 °C / 1 cycle of 1 min 95°C, 30s 55°C, 30s 95°C. In 1-step RT-qPCRs, each primer was applied at a final concentration of 0.1 pmol/µl and in 2-step RT-qPCRs at 0.15 pmol/µl. Each primer pair was tested for their efficiency using a RNA or cDNA serial dilution (1-step RT-qPCR: 0.2-200 ng RNA; 2-step RT-qPCR: 0.001-2 µl cDNA).
Each RNA sample was performed in duplicate to quadruplicate in qPCR and analyzed using MxPro software (Agilent Technologies). Samples were normalized to GAPDH (glyceraldehyde-3phosphate-dehydrogenase) and HMBS (hydroxymethylbilane synthase) (Vandesompele et al. 2002; Gutala and Reddy 2004) according to the relative quantification method (Bustin 2004) . SH-SY5Y cell samples were further normalized to controls, deducting the non-induced expression level.
Relative changes in gene expression levels (x-fold) were calculated according to T c 2   (Livak and Schmittgen 2001) . Dixons Q-Test was applied to exclude extraneous values to 99% significance (Dean and Dixon 1951) . Tissue RNAs that were heavily degraded were excluded from RT-qPCR experiments.
(Over)expression of the ALZAS gene in the human neuroblastoma cell line SH-SY5Y using the Regulated Mammalian Expression System (Promega)
The human neuroblastoma cells SH-SY5Y (LGC Standards) were first stably transfected with the regulator vector pReg neo (Promega) (SH-SY5Y-pReg neo) and, subsequently, transient transfected with the expression plasmid pF12A-ALZAS (SH-SY5Y-pReg neo-pF12A-ALZAS).
Stable transfection of pReg neo was performed after vector linearization. For that, pReg neo was treated for 3 hrs with the restriction enzyme XmnI according to the instruction manual (Thermo Fisher Scientific) and afterwards purified using the QIAquick Gel Extraction Kit (Qiagen).
The expression plasmid pF12A-ALZAS (clone 2, Supplementary Figure S1a ) was generated by cloning of human ALZAS gene sequence into the expression vector pF12A RM Flexi (Promega).
For detailed information regarding cloning process, see Supplementary section "Plasmids". Cell culture details are depicted in Supplementary section "Adherent Cell culture of human neuroblastoma cells SH-SY5Y". 48 hrs after transfection, SH-SY5Y-pReg neo cells were selected with geneticin disulfate (G418) solution (Carl Roth). For re-cloning, the cells were treated with 10% FBS/DMEM medium comprised of 88.8% v/v Dulbecco's modified eagle medium (DMEM, 1 g/l D-glucose, Thermo
Fisher Scientific) supplemented with 10% v/v fetal bovine serum (FBS, Sigma-Aldrich), 1% v/v hepes buffer (Sigma-Aldrich) and 0.2% v/v penicillin-streptomycin (500x, Roche). After 7 days of cultivation, G418 was added again. To confirm the integration of pReg neo in the genome of SH-SY5Y, total RNA was isolated as described above followed by 2-step RT-qPCR with the primer pair pReg neo-f1 and pReg neo-r1 (Table S2 ).
The appropriate G418 concentration for selection of SH-SY5Y-pReg neo cells (Southern and Berg 1982) was determined. For that, the SH-SY5Y cells were treated with varying concentrations of G418 from 0 µg/ml (control) up to 1000 µg/ml over a time interval of 1-12 day(s). The viability of the adherent cells was investigated by a live/dead staining with propidium iodide (Supplementary Figure S2b ). Finally, SH-SY5Y-pReg neo cells were maintained at 600 µg/ml G418 concentration.
The second transfection of the pF12A plasmid pF12A-ALZAS, pF12A-ALZASinv or pF12A-hRluc (the latter two serves as control) was performed as described below and before every new gene expression experiment. The control plasmid pF12A-ALZASinv was utilized in case of ALZAS protein analysis, pF12A-hRluc (kindly provided from Promega) for the analysis of different SH-SY5Y-pReg neo clones and water (no-template) was transfected as a control for
Renilla Luciferase Assay or ALZAS mRNA verification. For detailed information regarding measurement of luciferase activity see Supplementary section "Luciferase assay".
To induce (over)expression of the gene cloned into the pF12A plasmid, the SH-SY5Y-pReg neo cells were treated with coumermycin (Promega) after transfection mixture was removed. The inductor was diluted to the desired concentration (7-500 nM) in 10% FBS/DMEM medium containing G418. Controls transfected with pF12A-ALZASinv or sterile water (no-template) were also treated with coumermycin. To determine the basal expression level of ALZAS or Renilla luciferase, one well of cells was not treated with coumermycin (= non-induced SH-SY5Y-pReg neo-pF12A cells). Supplementary Figure S2a illustrates a schematic timetable for the ALZAS gene (over)expression studies in the human neuroblastoma cell line SH-SY5Y.
Plasmid transfection into SH-SY5Y
Prior to transfection procedure, the SH-SY5Y cells were plated at a density of 100,000 cells/cm 2 .
One day later, the plasmid was inserted into SH-SY5Y under sterile conditions using the Lipofectamine 2000 Kit according to manufacturer's instructions (Thermo Fisher Scientific). The cells were incubated with the transfection mixture for 3 hrs (for pF12A-ALZAS, pF12A-hRluc, pEGFP-ALZAS, pEGFP-C1) or 6 hrs (only for linearized pReg neo or pF12A-ALZAS) at 37°C, 5% CO 2 and saturated humidity. The mixture was removed and replaced by 10% FBS/DMEM medium.
In vitro translation
For in vitro translation, a DNA construct was synthesized comprised of a T7 promoter followed by the coding sequence EGFP and ALZAS and a poly(A) signal. For that, a PCR using the primers
T7pA-GFPA-f and T7polyA-A-r (Table S2 ) was performed, with the plasmid pEGFP-ALZAS clone 3 (Supplementary Figure S1b) Both PCR products (T7-EGFP-ALZAS-polyA, T7-EGFP-Fluc-polyA) were purified using QIAquick Gel Extraction Kit and the DNA sequence analyzed (T7-EGFP-ALZAS-polyA:
Supplementary Figure S1c , T7-EGFP-Fluc-polyA: DNA sequencing data not shown).
To synthesize proteins (EGFP-ALZAS or Fluc) from the PCR-generated DNA templates, either the was employed following instruction manuals. For detailed information regarding measurement of luciferase activity see Supplementary section "Luciferase assay".
Immunoprecipitation
The in vitro translation product EGFP-ALZAS was mixed with GFP-binding agarose beads (Chromotek gta) according to the instruction manual and incubated for 1 hr at 4°C. Dilution buffer was supplemented with 1 mM phenylmethylsulfonyl fluoride (Roth) and protease inhibitor. The beads were washed three times with ice cold PBS and finally resuspended in 20 µl 1-fold laemmli buffer (62.5 mM Tris-HCl pH 6.8, 12% w/v SDS, 60% v/v glycerin (all Carl Roth), bromophenol blue (Sigma-Aldrich), freshly added 0.05 M DTT (Carl Roth)). After heating and centrifugation, the supernatant was removed (bound fraction with EGFP-ALZAS fusion protein). The beads were treated once more with 20 µl 1-fold laemmli buffer. 
Mass spectrometry-based protein sequencing of EGFP-ALZAS fusion protein
Coomassie stained band was excised and its protein content was digested overnight with trypsin.
The resulting peptide mixture was extracted twice with 5% formic acid and acetonitrile and analyzed by liquid chromatography tandem mass spectrometry (LC MS/MS) on an Ultimate3000
nanoLC system interfaced on-line to a LTQ Orbitrap Velos hybrid tandem mass spectrometer (both Thermo Fisher Scientific) as described (Vasilj et al. 2012) . Peptides were matched by MASCOT v.2.2.04 software (Matrix Sciences) search against the EGFP-ALZAS construct sequence.
SDS-PAGE
Proteins were separated in a SDS-PAGE (Laemmli 1970) . The protein concentration in tissues or cell lysates was measured using the Quant-iT Protein Assay Kit and the Qubit Fluorometer according to the instruction manual (Thermo Fisher Scientific). 30 µg of total protein amount, 10 µl of immunoprecipitation (IP) fractions or 2-4 µl in vitro translation product was prepared in laemmli buffer (final buffer concentration 1-fold). Protein samples were incubated for 10 min at 95°C followed by a centrifugation step for 2 min at 10,000 g (2,500 g for bound fraction of IP).
The protein samples were then loaded on a 14% Tris-glycine gel (Anamed) and separated by electrophoresis for 1 hr 45 min at 25 mA per gel and 125 V in Tris-glycine-SDS buffer (1.92 M glycine, 0.25 M Tris, 1% w/v SDS (all Carl Roth); buffer was filtered when using IP protein probes). A prestained protein marker (Thermo Fisher Scientific) was used to identify protein sizes.
For tissue and cell probes, the antigen ALZAS ct12 peptide (<10 kDa, Davids Biotechnology, Regensburg, Germany) was loaded as a control on the gel.
Immunoblotting
After SDS-PAGE, the protein samples were transferred to nitrocellulose membrane using iBlot Dry
Blotting System according to the instruction manual (blotting time 8 min) (Thermo Fisher Scientific). The membrane was blocked for 1-2 hrs at room temperature in 5% w/v skim milk powder (Carl Roth) in PBST (PBS, 0.1% v/v Tween 20 (Serva Electrophoresis)). PBS was used for washing: 1.37 M NaCl, 81 mM Na 2 HPO 4 , 14.7 mM KH 2 PO 4 (all Merck), 27 mM KCl (Sigma-Aldrich) and filtered when IP protein probes were analyzed.
After blocking, the membrane was incubated overnight at 4°C with primary antibody diluted in 1% w/v skim milk powder in PBST. Primary antibodies used are: anti-ALZAS (1:500-1:1000, polyclonal, rabbit, affinity purified IgG, Davids Biotechnology, Regensburg, Germany), anti-GAPDH (1:700,000, Merck MAB374), anti-GFP (1:2000, Abcam ab290), anti-beta Amyloid 1-13
(1:500, monoclonal, Abcam ab17331), anti-beta Amyloid 22-35 (1:5000, polyclonal, Abcam ab62658) or anti-beta Amyloid 1-14 (1:1000, polyclonal, Abcam ab2539). The membrane was washed three times for 10 min with PBST. Then, the membrane was incubated 1-2 hrs at room temperature with a secondary antibody diluted in 1% w/v skim milk powder in PBST. Secondary antibodies were conjugated to HRP (1:5000, Jackson ImmunoResearch anti-mouse 715-035-150 or anti-rabbit 711-035-152). The membrane was washed again three times for 10 min with PBST.
Protein samples on the membrane were visualized with ECL Western Blotting Detection Reagents and Analysis System (GE healthcare) by measuring the chemiluminescence in the Luminescent Image Analyzer LAS-300 (Fujifilm; 5 min acquisition time). Each tissue protein sample was performed at least in duplicates (separate blots) and their protein signals were quantified using ImageJ software.
Immunocytochemistry and fluorescence microscopy
For immunocytochemical staining, we used following adherent cells: SH-SY5Y, human fibroblasts, dopaminergic neurons (cell line T12.9, differentiated 24 days following Reinhardt et al. software.
Cell viability tests
Live cell imaging of adherent cells
Adherent SH-SY5Y cells were maintained in a small incubator (37°C, 5% CO 2 , saturated humidity) connected to the fluorescence microscope DMIRE2 (Leica). Using Leica FW 4000 v1.1SP1 software and time-lapse microscopy, cells were recorded in phase contrast images every 15 min over a time period of 24 hrs.
Live/dead staining of adherent cells with propidium iodide
The medium was removed under sterile conditions and the adherent SH-SY5Y cells rinsed with PBS. 500 µl/2 cm 2 of freshly prepared staining solution was added to the cells and incubated for at 
Statistical analysis
Data are expressed as mean ± standard deviation. All statistical analyses were performed and figures created using Excel or GraphPad Prism 5.0 software.
Results
ALZAS gene expression studies in human tissues
In initial expression experiments, mRNA of the nested gene ALZAS was verified in frontal cortex of non-demented controls and AD patients by reverse transcriptase-quantitative real-time PCR (RT-qPCR) (Kienzl et al. 2006) . So far, no data exist as to whether ALZAS transcription and translation show tissue-and/or disease-specific variations. Therefore, we first investigated organs differing in structure and function from persons of divergent age and sex. qPCR amplification of ALZAS mRNA was performed using primer pairs with reverse primers being located within an intron of APP (Figure 2a ). On the other hand, the APP primer was designed to not detect ALZAS.
All applied primer pairs exhibited PCR-efficiencies between 95-105%.
The analysis of different brain tissues (cortex (gray and white matter), occipital lobe, brainstem, hippocampus, precentral gyrus, postcentral gyrus) and the peripheral organs (heart, liver, spleen, skeletal muscle, blood and placenta) revealed an overall weak expression of ALZAS independent of sex (selected tissues shown in Figure 2b-d) . A considerable difference in the mRNA level of ALZAS in the brain of non-AD controls and AD patients was not observed (Figure 2b) , confirming previous results from our group (Kienzl et al. 2007 ). Nevertheless, a tissue-specificity in the ALZAS expression could be noticed (Figure 2b, c) . While our investigations suggest a high ALZAS mRNA level in the heart of an AD patient (Figure 2c ), the lowest ALZAS mRNA amount was verified in blood of children (Figure 2b ). Comparing the expression of the nested gene ALZAS with its host gene APP, a consistent difference was revealed (Figure 2d ). In almost all the tissues tested, the expression of ALZAS was nearly 1000-fold lower than the expression of APP.
In Western blot analysis, we detected protein bands interacting with anti-ALZAS antibody at approximately 60 kDa in the brain (Figure 2e ), but in the peripheral tissues, heart and liver, we could observe additional bands at about 10 and 30 kDa (Figure 2f ). In the placenta samples, only protein bands at about 10 and 30 kDa were identified (data not shown). Depending on the tissue type the protein bands exhibit distinct intensities. While no signals could be detected in spleen and skeletal muscle, the strongest signals were observed in the liver of an AD patient (Figure 2f ).
Divergent signal intensities were found in brain (Figure 2e ). Obviously weaker signals were noticed in cortex in comparison to the hippocampus. Further, no evident differences could be observed between non-AD controls and AD patients in cortex and hippocampus. . Data is presented as mean ± SD determined from at least duplicate measurements. Placenta and gray matter (both non-AD) n = 11, heart (non-AD) and gray matter (AD) n = 7, white matter (AD) n = 5, blood children and white matter (both non-AD) n = 4. (e, f) Tissue lysates from brain and peripheral tissues were immunoblotted for ALZAS and GAPDH. Representative blots are shown. For better illustration, vertical blot lanes were partially rearranged. Lanes originated by different blots are separated. Asterisks indicate protein bands interacting with anti-ALZAS antibody (labeled as *) at about 10, 30 and 60 kDa or with anti-GAPDH (labeled as **) at 36 kDa. The ratio of the chemiluminescence signals from ALZAS and GAPDH were calculated. Data is shown as mean ± SD determined from at least triplicate measurements. Heart (non-AD) n = 8, cortex (non-AD) n = 4, hippocampus (non-AD) and hippocampus (AD) n = 3, cortex (AD) n = 2, liver (non-AD), heart and liver (both AD) n = 1. GAPDH: Glyceraldehyde-3-phosphate-dehydrogenase, HMBS: Hydroxymethylbilane synthase.
Analysis of ALZAS gene (over)expression in human neuroblastoma cells SH-SY5Y
To date, nothing is known about the role and importance of ALZAS in human cell metabolism.
Thus, we performed cell culture experiments in the human neuroblastoma cell line SH-SY5Y to examine the effects of regulated ALZAS (over)expression. To this end, we cloned the ALZAS gene in the controllable expression vector pF12A RM Flexi ( Supplementary Figure 1a) which is part of a regulated expression system (Zhao et al. 2003) . The second part of this system consists of the regulator vector pReg neo which allows for concentration-dependent gene expression of proteins potentially toxic to cells.
We first introduced the regulator vector pReg neo into the genome of SH-SY5Y cells to control the influence of the site of genome integration on basal (non-induced condition) and increased (induced) expression of ALZAS. 12 different neomycin resistant clones (SH-SY5Y-pReg neo) were transfected with the reporter plasmid pF12A-hRluc and several conditions, like different inductor concentrations and induction periods, were tested to identify clones with a low basal expression and a high expression under inducing conditions (Figure 3a) . The two clones, no. 2 and 8, showed a low basal Renilla luciferase activity (Figure 3a) , but differed by a factor up to 20 when comparing to the induced expression ( Figure 3b ). Both clones were chosen for subsequent ALZAS (over)expression studies on transcriptional (mRNA analysis by qPCR) and translational (protein analysis by immunoblotting, analyzing cell viability with live/dead staining) level.
To analyze ALZAS (over)expression, we transfected the SH-SY5Y-pReg neo clones 2 and 8 with the pF12A-ALZAS plasmid. Herein, we verified that a 12 hrs induction period yielded the highest ALZAS mRNA levels for both clones (Figure 3c ). For clone 2, concentration of 200 nM was optimal to achieve highest ALZAS mRNA levels (>200-fold increase compared to controls). For clone 8, 10 nM coumermycin was ideal to obtain a >500-fold increase in ALZAS gene expression.
Induction intervals above 24 hrs (36, 48 hrs) or an extended transfection duration of 6 hrs led to no further increase of ALZAS mRNA level in cells of SH-SY5Y-pReg neo-pF12A-ALZAS clone 2 (data not shown).
Western blot analyses with extracts from ALZAS overexpressing cells revealed protein bands
interacting with anti-ALZAS antibody in the cell extract and in the supernatant (Figure 3e . Data is presented as mean determined from at least duplicate measurements. (d) 24 hrs after induction, a live/dead staining was performed. The number of dead cells compared to controls (described in material and methods) is illustrated. (e, f) SH-SY5Y-pReg neo clone 2 (e) or clone 8 (f) was transfected for 3 hrs with pF12A-ALZAS and followed by induction of ALZAS expression (n = 2). Controls (no-template, Rluc, ALZASinv) were included. After 12 and 24 hrs, cell lysates were immunoblotted for ALZAS and GAPDH. For better illustration, vertical blot lanes were partially rearranged. Lanes originated from different blots are separated. Asterisks indicate protein bands interacting with anti-ALZAS antibody at about 30, 38, 60 and 100 kDa. ALZASinv: inverse ALZAS coding sequence, ni: non-induced, RLU: Relative Light Unit, Rluc: Renilla luciferase.
Verification of the specificity of anti-ALZAS antibody for ALZAS protein and examine the binding of A-antibodies to ALZAS protein
In the current study, we used a specifically produced anti-ALZAS antibody for all ALZAS protein detections. This antibody detects the same amino acid sequence (ct12) as the autoantibody found in human blood. To confirm the anti-ALZAS specificity, we performed IP followed by MS-based identification of ALZAS protein. IP-based purification of EGFP-ALZAS fusion protein generated in SH-SY5Y cells did not reach the required protein amount for MS measurement, although we employed cell lysates with the highest protein amount after 18 hrs ( Supplementary Figure 3a) . Figure S3b) . In Western blot analysis, we detected the EGFP-ALZAS fusion protein with anti-GFP antibody as well as with the anti-ALZAS antibody and antibeta Amyloid antibody recognizing amino acids 1-13 ( Figure 4b ). Further, we verified the identity of the EGFP-ALZAS fusion protein in a clinically applied, commercially available ELISA test for A 42 (INNOTEST -AMYLOID (1-42) , Fujirebio; data not shown). However, tested polyclonal Aantibodies interacting with A 1-14 or A 22-35 did not detect EGFP-ALZAS. 
Cell localization of the ALZAS protein
To identify the localization of the ALZAS protein in human, especially neuronal cells, we conducted immunocytochemical staining and analyzed them by fluorescence microscopy. We costained ALZAS (using anti-ALZAS antibody) with APP or markers for the cytoskeleton (F-actin), the endoplasmatic reticulum (protein disulfide isomerase, PDI), the Golgi apparatus (Golgi matrix protein of 130 kDa, GM130), mitochondria (Cytochrome C), lysosomes (Cathepsin) or endosomes (Ras-related in brain Rab5, Rab7). Fluorescence microscopy revealed a punctate pattern of ALZAS staining and a colocalization with the endoplasmatic reticulum (Figure 5a, b) , APP (Figure 5a ) or early endosomes (Rab5; Figure 5c ), as indicated in yellow. An overlay with other cell organelles was not evident (Supplementary Figure S4 ). Further investigations in human tissue suggested a localization of ALZAS within the cell membrane as well as in cytoplasm based on Western blot analysis (data not shown).
No considerable differences were observed between SH-SY5Y control cells and ALZAS
overexpressing SH-SY5Y-pReg neo-pF12A-ALZAS cells (clone 2 and 8). Cells of SH-SY5Y-pReg neo-pF12A-ALZAS clone 8 (non-induced) exhibited a remarkable staining with considerable accumulations around the nucleus and cell membrane (Figure 5b, indicated by arrows) . Co-staining of endogenous ALZAS and the EGFP-ALZAS fusion protein in SH-SY5Y-pEGFP-ALZAS cells revealed no overlapping fluorescence signals for the two proteins (Figure 5d ). Additionally, staining of ALZAS and organelles in SH-SY5Y-pEGFP-ALZAS cells exhibited no colocalization (Supplementary Figure S4b) . 
Discussion
The ALZAS gene represents a special type of nested gene because it is located on the same DNA strand as the host gene, consists of exon and intron sequences of APP and occupies the same reading frame (Figure 1 ) (Bergmann and Preddie 1998) . Mostly, eukaryotic nested genes, which are a specific class of overlapping genes, are encoded on the opposite DNA strand of the host gene (Gibson et al. 2005) , either within a large intron (intronic nested genes) or a protein coding DNA sequence (non-intronic nested genes) (Kumar 2009 ). Just a third of nested genes are localized on the same DNA strand as the host gene (Yu et al. 2005) . These different gene structures, especially the type and length of overlapping base pairs between nested and host gene, affect the relation of expression level of both genes (Ho et al. 2012) . Rarely do host and nested gene exhibit the same expression level (Sanna et al. 2008) . Accordingly, in the present study, we observed an approximately 1000-fold lower expression of ALZAS in tissues compared to APP (Figure 2d ).
ALZAS exhibited an ubiquitous transcription profile independent of sex and AD disease (Figure 2b , c) disconfirming initial hypotheses that ALZAS is either expressed solely in AD patients or overexpressed in AD brains (Bergmann et al. 1996; Kienzl et al. 2002; Kienzl et al. 2007 ).
Furthermore, we confirmed a tissue-specific transcription of ALZAS as was already validated for APP (Kummer et al. 2002; Ge et al. 2004) . Only 22% of protein coding human nested genes feature a tissue-specific expression (Yu et al. 2005; Ho et al. 2012) . In blood of children, we verified the lowest ALZAS mRNA level. As different transcription profiles are ascribed to a stronger regulation of transcription (Viskochil et al. 1991; Yu et al. 2005; Ho et al. 2012) , we assume that ALZAS is subject to a dual control system under normal conditions since it is part of two precursor mRNAs (its own and from APP). A separate promoter region for ALZAS is postulated to be located within intron 15 of the APP gene, consisting of heat shock and estrogen responsive elements (Bergmann and Preddie 1998) . Other regulatory post-transcriptional mechanisms exist includes RNA accumulation prior to degradation (Henikoff and Eghtedarzadeh 1987) or the stabilization of mRNA through binding of natural antisense transcripts (NATs) (Werner and Sayer 2009 ) which might apply for ALZAS. However, further investigations are required to identify specific ALZAS transcription factors. Simultaneous transcription of ALZAS and APP may trigger interferences like steric hindrance of both polymerases and/or ALZAS regulator proteins (Gibson et al. 2005) .
Unfortunately, in the present study, a linked expression of ALZAS and APP could neither be confirmed nor disproved.
We obtained exceptional data in human placenta samples where we measured an ALZAS mRNA concentration similar to that in brain and other peripheral tissues (data not shown). Usually, in humans, the placenta-transcriptome is unique (Kim et al. 2012) . To underscore our tissue-specific expression of ALZAS and to investigate a statistical significance for ALZAS expression pattern, we suggest that other tissues and/or a much bigger amount of different tissues should be examined.
Further, additional studies are required to verify a potential age-and disease-dependent transcription of ALZAS.
In the current study, analyses of ALZAS translation and protein amount in various tissues were performed for the first time, except for an enzyme-linked immunosorbent assay (ELISA) from human serum, which revealed an elevated amount of ALZAS protein in late clinical AD stages (Kienzl et al. 2007) . Our investigations in the brain (see Table S1 ) revealed no considerable differences in protein signals of non-AD controls and AD patients (Figure 2e ). However, we did observe different sizes and intensities of protein bands interacting with anti-ALZAS antibody for each tissue. We postulate that the ALZAS protein (calculated size of monomer is about 9 kDa) develops stable oligomeric structures which are part of ADDLs, as was established for A-peptides (Klein et al. 2001) . A-ADDLs are heterodisperse molecules consisting of soluble oligomers of different sizes (dimers to up to 24mers) whose amount is elevated in AD-affected brain regions (Klein 2002) . While A-ADDLs are mainly constituted of trimers to up to pentamers (Chromy et al. 2003) , our Western Blot analyses suggest that ALZAS might form hexamers in brain and probably hexamers and trimers in liver. The existence of stable oligomer formation, even under reducing conditions of denaturing SDS-PAGE, has been determined for A-peptides (Enya et al. 1999 ) and is also probable for ALZAS which contains the entire A 42 -sequence. It might also be possible that ALZAS form oligomeric structures along with A-peptides. In previous immunohistochemical studies, ALZAS could be detected in amyloid plaques using anti-ALZAS antibody . The aggregation of A 42 -peptides is ascribed either to (I) the hydrophobic C-terminus (amino acids 17 to 42) (Jarrett et al. 1993 ), (II) -sheet conformation (Liao et al. 2007 ), (III) pH value, (IV) protein concentration (Lansbury 1999) or (V) stability of the native, soluble protein (Dobson 2001) . The shape of A-oligomers is further influenced by their soluble or membrane-bound nature. Soluble A-species appear in monomers to hexamers, while membrane-associated A-peptides form larger aggregates (Johnson et al. 2011) . To confirm our considerations of ALZAS aggregation we recommend the analysis of the different sized ALZAS oligomers. Moreover, it is necessary to examine a bigger variety of organs for their ALZAS protein pattern.
A comparison of transcription and translation levels of ALZAS in human tissues revealed no correlation between mRNA and protein levels, which are described for many other genes, as well.
Weakly expressed genes mostly possess no correlation between mRNA and protein level (Maier et al. 2009 ). Contrary to the ALZAS mRNA level, we detected prominent protein signals in liver ( Figure 2f ) and none in skeletal muscle of an AD patient (data not shown). Previously, attenuated levels of A-peptides have been observed in liver of AD patients (Roher et al. 2009 ). Here we postulate that, not only APP but also ALZAS represents a source of A-peptides and the probably high amount of ALZAS protein in AD liver may evoke an increased A 42 -concentration, being rediscovered as amyloid plaques in AD brain. Since non-demented controls also exhibit an elevated A-concentration in liver, it is unclear if the liver sequesters or is the source of A-peptides (Sagare et al. 2011) .
Investigations concerning the discrepancy between mRNA and protein amount of ALZAS are necessary to understand the regulation of ALZAS gene in detail. It might be influenced by APP mutations in exon 16/17 (Bergmann and Preddie 1998) prior to post-transcriptional regulation, for instance, RNA interference (Meister 2007) or NATs, which influence mRNA processing, RNA transport and tissue-associated translation (Werner and Sayer 2009) . Moreover, ALZAS gene regulation could be affected at post-or co-translational level because the obviously impaired ubiquitin proteasome system (UPS) in AD patients (Oddo 2008) In contrast to tissue samples, we detected different protein bands interacting with anti-ALZAS antibody in the SH-SY5Y cells (Figure 3e , f). We assume that this pattern reveals different oligomer formations of ALZAS. This observation might correlate with the size of A-oligomers which vary in cell specific manner (Klein 2002) . The apparently unchanged protein amount in induced ALZAS overexpressing cells compared to controls (Figure 3e , f, Supplementary Figure   S2c ) is in accordance with the facts that no considerable increase in cell death (Figure 3d ) and no higher intensity of ALZAS fluorescence signals (Figure 5b, c) were observed upon overexpression.
Since anti-ALZAS antibody could not distinct between endogenous and overexpressed (induced condition) ALZAS protein, we have estimated to find stronger signals in ALZAS overexpressing cells through higher ALZAS protein amount. Furthermore, we did not detect ALZAS protein in detached ALZAS overexpressing SH-SY5Y cells (data not shown).
However, since the Renilla luciferase assays unraveled an inductor concentration-dependent translation (Figure 3a, b) , it might be assumed that an enhanced amount of ALZAS protein could have negative effects on human cell metabolism. Thus, post-transcriptional and/or posttranslational regulation mechanisms limit the amount of ALZAS protein in overexpressing cells.
This apparently strong, regulation of ALZAS implies a considerable function of the protein in cell metabolism, as expected for all human nested genes (Yu et al. 2005) . To date, it is a general belief that ALZAS is a transmembrane protein which could be integrated in the membrane similar to or instead of APP because ALZAS possesses the whole transmembrane domain of APP (Figure 1 ) (Jellinger et al. 2008) . As we were able to detect ALZAS in the supernatant of overexpressing cells (Figure 3e, f) , we speculate that it might have crossed the membrane by secretion. For A-peptides, it has been validated that they are secreted followed by the extracellular deposition (Dobson 2001) .
However, in AD, A-release may occur initially after cell death (Recuero et al. 2004 ).
Amphiphilic properties are affirmed for ALZAS and also for peripheral membrane proteins which are not stably embedded in the membrane and thus can be liberated (Bhardwaj et al. 2006 ). Our investigation, using a protocol for fractionated protein isolation, indicated that ALZAS is localized in the membrane and the water-soluble protein fraction (data not shown). Further hints that ALZAS might be a peripheral membrane protein, for example, in vesicles, were found in immunocytochemical staining. The abundant ALZAS staining near the cell membrane and around the nucleus (Figure 5a -c) showed a predominant overlay with Rab5 protein (Figure 5c ), a peripheral membrane protein in early endosomes involved in cellular signal transduction (Chavrier et al. 1990 ). An overlay of ALZAS and APP was observed more in the cell membrane/cell surface (Figure 5a) , where APP is spliced in the non-amyloidogenic pathway (-cleavage) (Kojro and Fahrenholz 2005) . On the contrary, the amyloidogenic cleavage occurs mainly in endosomes (Vassar et al. 1999 ). However, the EGFP-ALZAS fusion protein showed a divergent localization to endogenous ALZAS (Figure 5d ) which might indicate that, upon fusion of EGFP to the N-terminal, a crucial transport signal of ALZAS is lost. In contrast, the EGFP-Rab5 fusion protein showed colocalization with endogenous Rab5 in cytoplasmic vesicles (Hoffenberg et al. 2000) . However, similar to ALZAS, Rab5 is ubiquitously expressed and undergoes aggregation. An overexpression of Rab5 achieved no significant enhanced membrane staining (Chavrier et al. 1990 ) which is analogous to our immunocytochemical staining in ALZAS overexpressing SH-SY5Y cells.
In addition to Rab5, the APP protein and the -amyloid cleaving enzyme 1 (BACE1), mediating -secretase cleavage of APP, are prevalently localized in early endosomes (Kinoshita et al. 2003) , and more precisely, in the membrane structure termed lipid raft, which represent the primary place of cellular signal transduction (Fantini et al. 2002) . Several proteins encoded by nested genes are involved in cell-cell communication and our studies suggest that ALZAS may play a similar role.
Comparing the cellular functions of nested and host genes, a correspondence is rarely observed (Yu et al. 2005 ). However, APP may perform a regulatory function as a receptor or in cell adhesion (Sondag and Combs 2004; Sosa et al. 2013) . Interestingly, prevention of APP -cleavage did not result in endosome dysfunction which is typical for patients in early AD stages (Jiang et al. 2010 ).
In addition to extensive transcription, translation and cell localization studies, we could, for the first time to our knowledge, prove the ALZAS amino acid sequence and the specificity of anti-ALZAS antibody produced using the antigenic peptide ct12 that act as immunogenic sequence in humans.
Using EGFP-ALZAS fusion protein produced in vitro, we confirmed the specific attachment of anti-ALZAS antibody to ALZAS, while the tested monoclonal A 1-13 -antibody recognized both ALZAS ( Figure 4b ) and A 40 . Moreover, the tested monoclonal A 37-42 -antibody, a commercially available ELISA test for diagnosis of AD, recognized both the A 42 and the EGFP-ALZAS fusion protein, revealing that this assay is not specific for A 42 but may as well detect ALZAS. However, we could not detect EGFP-ALZAS with tested polyclonal A-antibodies interacting with A 1-14 or A 22-35 , indicating a conformational divergence of epitopes. Taken together, immunodetection of A-peptides in former studies come under suspicion of co-detecting ALZAS.
Considering that highest ALZAS autoantibody concentrations were observed in patients with early AD, we agree with earlier assumptions that ALZAS could serve as an indicator for AD development and may be a diagnostic blood marker (Bergmann and Preddie 1998) . With respect to AD-specific expression of ALZAS, further investigation are necessary to confirm the presence of ALZAS in amyloid plaques and its function in the human. In conclusion, the present study demonstrates that ALZAS has the potential to be a novel and crucial factor in AD pathology.
